Daiichi Sankyo and MSD have expanded their partnership to globally develop and commercialize three DXd antibody-drug conjugates, including MSD’s DLL3-targeting T-cell engager, MK-6070

MK-6070, acquired by MSD through Harpoon Therapeutics, is being evaluated in Phase I/II trials for small cell lung cancer and neuroendocrine tumors

The collaboration will involve joint development and commercialization of MK-6070 globally, with MSD holding exclusive rights in Japan and responsible for its manufacture and supply

MSD will receive a $170 million upfront payment and the companies will share R&D costs and global profits from MK-6070, while Daiichi Sankyo will earn sales-based royalties

This expanded agreement builds on a prior partnership to develop and commercialize three investigational DXd ADCs, with Daiichi Sankyo retaining exclusive rights in Japan and the companies sharing R&D expenses for MK-6070 in combination with ifinatamab deruxtecan